SITC is committed to maintaining full transparency in our clinical practice guideline development process, in alignment with the Institute of Medicine’s standards, for the ultimate purpose of developing quality clinical practice guidelines to aid practitioners in providing the best possible care to their patients. The public open comment period allows for key stakeholders and other experts in the field – both within and outside of our membership – to provide comment on the confidential manuscript draft prior to publication.
SITC clinical practice guidelines equip clinicians with the knowledge to utilize newly approved agents, guidance on patient selection, biomarker testing, and management of immune-related toxicities, in addition to providing expert insight for what’s on the horizon in immunotherapy treatment options.
All participants must complete and sign a non-disclosure and confidentiality agreement prior to obtaining the draft manuscript. All comments must be received by the noted deadline to be considered.
All comments received during the open comment period will be reviewed by the applicable Expert Panel leadership. Comments are advisory only and SITC is not obligated to make any suggested changes based on comments received. SITC will consider all submissions but will not respond directly to individual commenters. If you have any further questions, please contact firstname.lastname@example.org.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com